Revance Therapeutics receives permanent J-code for DAXXIFY, its cervical dystonia treatment, with positive ASPEN-1 Pivotal Phase 3 study results published in Neurology®.
Revance Therapeutics, Inc. has received a permanent J-code for its product DAXXIFY, which is indicated for the treatment of cervical dystonia in adults. J-Codes are used by commercial insurance plans, Medicare, and other government payers for reimbursement purposes. In addition, Revance announced the publication of results from the ASPEN-1 Pivotal Phase 3 study in Neurology®, reinforcing the product's long duration of effect and favorable safety profile.
February 02, 2024
6 Articles